A US district court yesterday (March 17) gave its opinion on how a group of disputed patent claims must be construed in a patent infringement case between Eisai and Novartis and several generic drug makers.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Eisai, Novartis, Glenmark, claim construction, patent infringement, patent